BL
ATNM icon

BFSG LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

BFSG LLC’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$630 – 676
2024
Q4 		$630 Hold
500
– – ﹤0.01% 644
2024
Q3 		$940 Hold
500
– – ﹤0.01% 607
2024
Q2 		$3.7K Hold
500
– – ﹤0.01% 538
2024
Q1 		$3.92K Hold
500
– – ﹤0.01% 560
2023
Q4 		$2.54K Buy
+500
New +$2.58K ﹤0.01% 536

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFSG LLC's ATNM Position: Q1 2025 in Review

BFSG LLC sold out of Actinium Pharmaceuticals (ATNM) in Q1 2025, closing a stake of 500 shares — an estimated $630 sold.

BFSG LLC first reported a position in ATNM in Q4 2023 and held it in 5 quarters. The position peaked at $3.92K in Q1 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q1 2025.

  • BFSG LLC reported no remaining Actinium Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 500 Actinium Pharmaceuticals shares in Q1 2025, an estimated $630.
  • BFSG LLC first reported a position in Actinium Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • BFSG LLC's Actinium Pharmaceuticals position peaked at $3.92K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.